1. Scrip
  2. >>Business
  3. >>Earnings

Carry On Cosentyx As Novartis Lines Up More Blockbusters

 
• By Kevin Grogan

The Swiss giant has posted a strong set of results with the company highly confident that its flagship immune drug can keep the competition at bay.

Novartis
CEO Narasimhan gives his end-of-year report • Source: Novartis

Novartis AG is aiming to launch 10 potential blockbusters by 2020 but for the moment, the Swiss major is reaping the benefits from an established big seller – Cosentyx (secukinumab) – which is continuing to grow at an impressive rate.

Speaking at Novartis' annual press conference in Basel on Jan. 30, chief executive Vas Narasimhan highlighted how much of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.